Patent Document ID: 20170202984
Application ID: 15359675
Patent Status: 0

Claim One:
1. A compound comprising the structure: or a pharmaceutically acceptable salt thereof, wherein: R 1 is selected from the group consisting of hydrogen, alkyl optionally substituted, heteroalkyl optionally substituted, alkoxy optionally substituted, alkoxyalkyl optionally substituted, aryl optionally substituted, heteroaryl optionally substituted, and an imaging moiety; R 2 is selected from the group consisting of hydrogen, alkyl optionally substituted, heteroalkyl optionally substituted, alkoxy optionally substituted, alkoxyalkyl optionally substituted, aryl optionally substituted, heteroaryl optionally substituted, halo, haloalkyl, —NO 2 , and an imaging moiety; R 3 is selected from the group consisting of hydrogen, alkyl optionally substituted, heteroalkyl optionally substituted, alkoxy optionally substituted, alkoxyalkyl optionally substituted, aryl optionally substituted, heteroaryl optionally substituted, halo, haloalkyl, —CN, —NO 2 , and an imaging moiety; J is selected from the group consisting of N(R 7 ), S, O, C(═O), C(═O)O, OC(═O), C(═O)N(R 7 ), N(R 7 )C(═O), CH 2 O, and a bond; R 4 and R 5 are each independently selected from the group consisting of hydrogen, alkyl optionally substituted, and an imaging moiety, or optionally any two of R 4 and R 5 are joined together to form a ring; n is 0, 1, 2, or 3; W is heteroaryl, naphthyl, heterocyclyl, or aryl; each R 6 is independently selected from the group consisting of hydrogen, alkyl optionally substituted, alkenyl optionally substituted, alkynyl optionally substituted, heteroalkyl optionally substituted, alkoxy optionally substituted, aryloxy optionally substituted, heteroaryloxy optionally substituted, alkoxyalkyl optionally substituted, aryl optionally substituted, heteroaryl optionally substituted, halo, haloalkyl, —N(R 7 ) 2 , —NO 2 , —OH, —C(═O)R 8 , —C(═O)OR 8 , —OC(═O)R 8 , —C(═O)N(R 7 ) 2 , —N(R 7 )C(═O)R 8 , —CN, —Si(R 9 ) 3 , —B(R 9′ ) 3 , —OR 8 , and an imaging moiety; m is 0, 1, 2, 3, 4, 5, 6, or 7; each R 7 is independently selected from the group consisting of hydrogen, alkyl optionally substituted, alkenyl optionally substituted, alkynyl optionally substituted, heteroalkyl optionally substituted, alkoxy optionally substituted, alkoxyalkyl optionally substituted, aryl optionally substituted, heteroaryl optionally substituted, halo, haloalkyl, and an imaging moiety, or optionally, any two R 7 may be joined together to form a ring; each R 8 is independently selected from the group consisting of hydrogen, alkyl optionally substituted, heteroalkyl optionally substituted, alkoxyalkyl optionally substituted, aryl optionally substituted, heteroaryl optionally substituted, haloalkyl, and an imaging moiety; each R 9 is independently selected from the group consisting of hydrogen, alkyl optionally substituted, aryl optionally substituted, haloalkyl, halogen, and an imaging moiety; and each R 9′ is independently selected from the group consisting of halo, alkyl optionally substituted, aryl optionally substituted, and an imaging moiety, provided that at least one imaging moiety is present in the compound; and provided that when W is aryl, a) R 3 is not halo, alkyl or haloalkyl, or b) at least one R 6 is selected from the group consisting of alkynyl optionally substituted, alkenyl optionally substituted, alkyl substituted with —CN, alkyl substituted with —C(═O)OR 8 , alkyl substituted with —C(═O)R 8 , alkyl substituted with —N(R 7 ) 2 , —CN, —NO 2 , —N(R 7 ) 2 , —C(═O)OR 8 , —OC(═O)R 8 , —C(═O)R 8 , —C(═O)N(R 7 ) 2 , and —N(R 7 )C(═O)R 8 .